1. Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. 2. Department of Immunology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. 3. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. *Equal contributors
✉ Corresponding author: Prof. Feng Gao, Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, 6 ShuangYong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. Tel: (+86)-771-5356529. Fax: (+86)-771-5356585. Email: gaofengedu.cn.More
Citation:
Gong YZ, Ma H, Ruan GT, Zhu LC, Liao XW, Wang S, Yan L, Huang W, Huang KT, Xie H, Zhu GZ, Wang XK, Liao C, Gao F. Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. J Cancer 2021; 12(18):5506-5518. doi:10.7150/jca.51524. https://www.jcancer.org/v12p5506.htm
Objective: The objective was to identify and validate C-X-C motif chemokine ligand 1(CXCL1) for diagnosis and prognosis in colon adenocarcinoma (COAD).
Methods: Our current study had enrolled one The Cancer Genome Atlas (TCGA) cohort and two Guangxi cohorts to identify and verify the diagnostic and prognostic values of CXCL1 in COAD. Functional enrichment was performed by gene set enrichment analysis (GSEA).
Results: In TCGA cohort, the expression of CXCL1 was significantly up-regulated in tumor tissues and decreased as the tumor stage developed. The receiver operating characteristic (ROC) curve showed that CXCL1 had a high diagnostic value for COAD. The result of Kaplan-Meier survival analysis showed that CXCL1 gene expression (P=0.045) was significantly correlated with overall survival (OS) of COAD. Results of Guangxi cohort also verified the diagnostic value of CXCL1 in COAD, and sub-group survival analyses also suggested that patients with high CXCL1 expression were related to a favorable OS (Corrected P=0.005). GSEA revealed that CXCL1 high expression phenotype was related to cytokine activity, cell apoptosis, P53 regulation pathway, and regulation of autophagy in COAD.
Conclusions: In this study, we found that CXCL1 gene might be a potential diagnostic biomarker for COAD, and might serve as a prognostic biomarker for specific subgroup of COAD.
Gong, Y.Z., Ma, H., Ruan, G.T., Zhu, L.C., Liao, X.W., Wang, S., Yan, L., Huang, W., Huang, K.T., Xie, H., Zhu, G.Z., Wang, X.K., Liao, C., Gao, F. (2021). Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. Journal of Cancer, 12(18), 5506-5518. https://doi.org/10.7150/jca.51524.
ACS
Gong, Y.Z.; Ma, H.; Ruan, G.T.; Zhu, L.C.; Liao, X.W.; Wang, S.; Yan, L.; Huang, W.; Huang, K.T.; Xie, H.; Zhu, G.Z.; Wang, X.K.; Liao, C.; Gao, F. Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. J. Cancer 2021, 12 (18), 5506-5518. DOI: 10.7150/jca.51524.
NLM
Gong YZ, Ma H, Ruan GT, Zhu LC, Liao XW, Wang S, Yan L, Huang W, Huang KT, Xie H, Zhu GZ, Wang XK, Liao C, Gao F. Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. J Cancer 2021; 12(18):5506-5518. doi:10.7150/jca.51524. https://www.jcancer.org/v12p5506.htm
CSE
Gong YZ, Ma H, Ruan GT, Zhu LC, Liao XW, Wang S, Yan L, Huang W, Huang KT, Xie H, Zhu GZ, Wang XK, Liao C, Gao F. 2021. Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. J Cancer. 12(18):5506-5518.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.